ResearcherShanghai Skin Disease HospitalNo recent work listed

Hang Chen

ORCID-verified (high confidence)As of 14 November 2026

Matched on ORCID iD 0000-0003-1410-4284; OpenAlex author ID A5100442532.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 1 (first author 1, last author 0)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 1

Papers, trials and grants by year

2023: 1 paper

Papers 1

Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhance inhibition in pancreatic cancer. First author DOI 10.1016/j.ijpharm.2023.123623 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Xin Wu · 1 shared paper, 2023
- Paper Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhanc… DOI 10.1016/j.ijpharm.2023.123623 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.